Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
DB Period (52 Weeks)	STARTED	Pamrevlumab	37
DB Period (52 Weeks)	STARTED	Placebo	36
DB Period (52 Weeks)	Received at Least 1 Dose of Study Drug	Pamrevlumab	36
DB Period (52 Weeks)	Received at Least 1 Dose of Study Drug	Placebo	36
DB Period (52 Weeks)	COMPLETED	Pamrevlumab	35
DB Period (52 Weeks)	COMPLETED	Placebo	36
DB Period (52 Weeks)	NOT COMPLETED	Pamrevlumab	2
DB Period (52 Weeks)	NOT COMPLETED	Placebo	0
OLE Period (52 Weeks)	STARTED	Pamrevlumab	34
OLE Period (52 Weeks)	STARTED	Placebo	35
OLE Period (52 Weeks)	Received at Least 1 Dose of Study Drug	Pamrevlumab	34
OLE Period (52 Weeks)	Received at Least 1 Dose of Study Drug	Placebo	34
OLE Period (52 Weeks)	COMPLETED	Pamrevlumab	0
OLE Period (52 Weeks)	COMPLETED	Placebo	0
OLE Period (52 Weeks)	NOT COMPLETED	Pamrevlumab	34
OLE Period (52 Weeks)	NOT COMPLETED	Placebo	35

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04632940/flow